Sarcoma therapeutics market to grow by $1.11b by 2028

The prevalence of patient assistance programmes is driving market growth.

The global market for sarcoma therapeutics will expand by $1.11 by 2028 at a compound annual growth rate (CAGR) of 8.51%, Technavio projected.

A key driver of this expansion is the prevalence of patient assistance programmes, alongside a rising focus on research and development (R&D) for new drugs for sarcoma treatment, particularly osteosarcoma.

Recent advancements include a focus on addressing challenges with current chemotherapy methods, such as side effects and drug resistance.

“Innovative strategies, including nanocarriers for targeted drug delivery, immunotherapy, and targeted therapy, are being explored to enhance treatment outcomes for osteosarcoma patients,” the report said.

Meanwhile, the market is also experiencing a trend towards manufacturing excellence and supply chain optimisation to deliver patient-centric solutions for different sarcoma types.